Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

被引：148

作者：

Kwa, ALH

Loh, CS

Low, JGH

Kurup, A

Tam, VH

机构：

[1] Singapore Gen Hosp, Dept Pharm, Singapore 169608, Singapore

[2] Singapore Gen Hosp, Dept Internal Med, Div Infect Dis, Singapore 169608, Singapore

[3] Univ Houston, Coll Pharm, Houston, TX 77030 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 41卷 / 05期

关键词：

D O I：

10.1086/432583

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies. © 2005 by the Infectious Diseases Society of America. All rights reserved.

引用

页码：754 / 757

页数：4

共 12 条

[1] Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
不详
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (04) : 388 - 416
[2] EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF RESPIRATORY-TRACT INFECTIONS
CHOW, AW
HALL, CB
KLEIN, JO
KAMMER, RB
MEYER, RD
REMINGTON, JS
[J]. CLINICAL INFECTIOUS DISEASES, 1992, 15 : S62 - S88
[3] Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria
Evans, ME
Feola, DJ
Rapp, RP
[J]. ANNALS OF PHARMACOTHERAPY, 1999, 33 (09) : 960 - 967
[4] Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units
Flournoy, DJ
Reinert, RL
Bell-Dixon, C
Gentry, CA
[J]. AMERICAN JOURNAL OF INFECTION CONTROL, 2000, 28 (03) : 244 - 250
[5] Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin:: A comparison with imipenem-susceptible VAP
Garnacho-Montero, J
Ortiz-Leyba, C
Jiménez-Jiménez, FJ
Barrero-Alodóvar, AE
García-Garmendia, JL
Bernabeu-Witteli, M
Gallego-Lara, SL
Madrazo-Osuna, J
[J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) : 1111 - 1118
[6] Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin
Hamer, DH
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (01) : 328 - 330
[7] COLISTIN INHALATION-THERAPY IN CYSTIC-FIBROSIS PATIENTS WITH CHRONIC PSEUDOMONAS-AERUGINOSA LUNG INFECTION
JENSEN, T
PEDERSEN, SS
GARNE, S
HEILMANN, C
HOIBY, N
KOCH, C
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (06) : 831 - 838
[8] Resistance patterns among nosocomial pathogens - Trends over the past few years
Jones, RN
[J]. CHEST, 2001, 119 (02) : 397S - 404S
[9] Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii
Levin, AS
Barone, AA
Penço, J
Santos, MV
Marinho, IS
Arruda, EAG
Manrique, EI
Costa, SF
[J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) : 1008 - 1011
[10] Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa
Linden, PK
Kusne, S
Coley, K
Fontes, P
Kramer, DJ
Paterson, D
[J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (11) : E154 - E160

← 1 2 →